Nimotuzumab for pediatric diffuse intrinsic pontine gliomas (Q37822466)

23 August 2017

1 reference

title

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas (English)

1 reference

23 August 2017

diffuse midline glioma

0 references

author

Maura Massimino

1

0 references

Veronica Biassoni

object named as

Veronica Biassoni

3

0 references

author name string

Udo Bode

2

1 reference

PubMed ID

21171927

23 August 2017

Gudrun Fleischhack

4

1 reference

PubMed ID

21171927

23 August 2017

language of work or name

English

0 references

publication date

21 December 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

247-256

1 reference

23 August 2017

2

1 reference

Management of pediatric pontine gliomas

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Advances toward an understanding of brainstem gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherap

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Treatment options in childhood pontine gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Prospective study of awake craniotomy used routinely and nonselectively for supratentorial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Nimotuzumab in pediatric glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Diffuse brainstem glioma in children: critical review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

A case of relapsing glioblastoma multiforme responding to vinorelbine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.546341

10.1517/14712598.2011.546341

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21171927